Pharsight

Tobi Podhaler generic

Tobi Podhaler is an anti-cystic fibrosis drug owned by Mylan Specialty LP. It contains tobramycin as the active ingredient and was first authorized for market use on March 22, 2013. It holds a total of 11 patents, with 3 of them having expired.

When will Tobi Podhaler generic be available?

The generic release of Tobi Podhaler is anticipated to happen after November 4, 2030. This is due to the expiry of the last patent of this drug, which is due on this date.

Tobi Podhaler uses

Tobi Podhaler can be used for the treatment of cystic fibrosis patients affected by Pseudomonas Aeruginosa. The active ingredient, tobramycin, aids in controlling the symptoms and progression of the disease.

Tobi Podhaler patent expiration

Tobi Podhaler holds 11 patents in total, with the last patent due to expire on November 4, 2030. Once expired, Tobi Podhaler generic versions can be released to the market. Below are the details of the patent:

EPO Oppostions filed on Tobi Podhaler

Litigations filed on Tobi Podhaler

Tobi Podhaler dosage

Want to ask something?